Sterling Investment Advisors (Pennsylvania)’s Nektar Therapeutics NKTR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-37
Closed -$2K 361
2022
Q2
$2K Hold
37
﹤0.01% 506
2022
Q1
$3K Hold
37
﹤0.01% 524
2021
Q4
$7K Hold
37
﹤0.01% 467
2021
Q3
$10K Hold
37
﹤0.01% 435
2021
Q2
$9K Hold
37
﹤0.01% 431
2021
Q1
$11K Hold
37
﹤0.01% 398
2020
Q4
$9K Hold
37
﹤0.01% 382
2020
Q3
$9K Sell
37
-266
-88% -$83.7K ﹤0.01% 352
2020
Q2
$105K Buy
303
+253
+506% +$78.9K 0.04% 156
2020
Q1
$13K Hold
50
0.01% 301
2019
Q4
$16K Hold
50
0.01% 314
2019
Q3
$14K Buy
50
+10
+25% +$3.67K 0.01% 321
2019
Q2
$21K Hold
40
0.01% 292
2019
Q1
$20K Sell
40
-293
-88% -$174K 0.01% 294
2018
Q4
$164K Buy
333
+133
+67% +$80.3K 0.1% 120
2018
Q3
$183K Buy
+200
New +$171K 0.1% 117
2018
Q2
Sell
-67
Closed -$106K 398
2018
Q1
$106K Buy
+67
New +$86.3K 0.07% 139
2017
Q4
Sell
-200
Closed -$72K 353
2017
Q3
$72K Hold
200
0.05% 153
2017
Q2
$59K Hold
200
0.04% 169
2017
Q1
$70K Hold
200
0.05% 151
2016
Q4
$37K Buy
+200
New +$40.7K 0.03% 172

Other funds holding NKTR

Sterling Investment Advisors (Pennsylvania)'s NKTR Position: Q3 2022 in Review

Sterling Investment Advisors (Pennsylvania) sold out of Nektar Therapeutics (NKTR) in Q3 2022, closing a stake of 37 shares — an estimated $2K sold.

Sterling Investment Advisors (Pennsylvania) first reported a position in NKTR in Q4 2016 and held it in 21 quarters. The position peaked at $183K in Q3 2018. 231 funds tracked by Wall St. Rank hold NKTR as of Q3 2022.

  • Sterling Investment Advisors (Pennsylvania) reported no remaining Nektar Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Sterling Investment Advisors (Pennsylvania) sold 37 Nektar Therapeutics shares in Q3 2022, an estimated $2K.
  • Sterling Investment Advisors (Pennsylvania) first reported a position in Nektar Therapeutics in Q4 2016 and held it in 21 quarters.
  • Sterling Investment Advisors (Pennsylvania)'s Nektar Therapeutics position peaked at $183K in Q3 2018.
  • 231 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2022.

Based on Sterling Investment Advisors (Pennsylvania)'s 13F filing for Q3 2022, filed 3 Nov 2022.